Celcuity, Inc. (CELC)
92.27
+1.48
(+1.63%)
USD |
NASDAQ |
Aug 25, 16:00
92.20
-0.07
(-0.08%)
After-Hours: 19:59
Celcuity Enterprise Value : 4.514B for Aug. 25, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 25, 2026 | 4.514B |
| August 24, 2026 | 4.442B |
| August 21, 2026 | 4.576B |
| August 20, 2026 | 4.431B |
| August 19, 2026 | 4.582B |
| August 18, 2026 | 4.562B |
| August 17, 2026 | 4.523B |
| August 14, 2026 | 4.501B |
| August 13, 2026 | 4.237B |
| August 12, 2026 | 4.505B |
| August 11, 2026 | 4.311B |
| August 10, 2026 | 4.442B |
| August 07, 2026 | 4.539B |
| August 06, 2026 | 4.562B |
| August 05, 2026 | 4.546B |
| August 04, 2026 | 4.525B |
| August 03, 2026 | 4.292B |
| July 31, 2026 | 4.226B |
| July 30, 2026 | 4.288B |
| July 29, 2026 | 4.074B |
| July 28, 2026 | 4.034B |
| July 27, 2026 | 4.025B |
| July 24, 2026 | 4.042B |
| July 23, 2026 | 4.322B |
| July 22, 2026 | 4.410B |
| Date | Value |
|---|---|
| July 21, 2026 | 4.486B |
| July 20, 2026 | 4.305B |
| July 17, 2026 | 4.324B |
| July 16, 2026 | 4.320B |
| July 15, 2026 | 4.477B |
| July 14, 2026 | 5.433B |
| July 13, 2026 | 5.078B |
| July 10, 2026 | 5.263B |
| July 09, 2026 | 5.554B |
| July 08, 2026 | 5.328B |
| July 07, 2026 | 5.662B |
| July 06, 2026 | 5.312B |
| July 02, 2026 | 5.282B |
| July 01, 2026 | 5.112B |
| June 30, 2026 | 5.119B |
| June 29, 2026 | 4.893B |
| June 26, 2026 | 4.769B |
| June 25, 2026 | 4.574B |
| June 24, 2026 | 4.596B |
| June 23, 2026 | 4.298B |
| June 22, 2026 | 4.284B |
| June 18, 2026 | 4.179B |
| June 17, 2026 | 4.193B |
| June 16, 2026 | 4.158B |
| June 15, 2026 | 4.203B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Cogent Biosciences, Inc. | 5.833B |
| Replimune Group, Inc. | 1.244B |
| Erasca, Inc. | 5.327B |
| Apogee Therapeutics, Inc. | 9.294B |
| Arrowhead Pharmaceuticals, Inc. | 12.32B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -78.86M |
| Total Expenses (Quarterly) | 78.86M |
| EPS Diluted (Quarterly) | -1.439 |
| Earnings Yield | -4.66% |
| Normalized Earnings Yield | -4.501 |